A patient with severe septic shock and ischemia zones on the skin and microthrombs. Credit: Emergency doc / commons.wikimedia.org.

Asep Medical (Asep) has unveiled new artificial intelligence (AI) technology for the rapid detection of infections associated with severe sepsis.

The new method has been developed by Hancock Lab under the supervision of Dr Robert Hancock, Killam Professor at the University of British Columbia in Canada.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The method studies the dysfunctional immune responses in sepsis to detect gene sets that can predict the likelihood of a patient developing severe sepsis.

Asep chair and CEO Dr Hancock said: “We have harnessed AI to obtain practical outcomes in areas of high unmet medical need, including identifying severe sepsis cases.

“Sepsis is a severe disease responsible for one in five deaths worldwide and essentially all deaths from severe Covid-19.

See Also:

“Typically, a patient arrives in the emergency room feeling profoundly ill, with fairly non-specific symptoms. Physicians are in a “look-and-see” game for the first 24–48 hours.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is planning a confirmatory clinical study to assess the performance of the Sepsettest on patients with sepsis.

It will be conducted at St. Paul’s Hospital in downtown Vancouver, British Columbia, Canada.

This trial will be carried out before initiating a larger study to assess the performance of sepsis diagnostic technology called Sepset. It will be compared with the existing sepsis tests to support the filing of a 510(k) submission with the US Food and Drug Administration, with the plan to complete this application process in the first quarter of next year.